HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Protein degraders gain speed as Arvinas scores landmark approval

Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrower-than-expected clinical benefit, R&D in the field is heating up.

By PharmaVoice · May 4, 2026 · via PharmaVoice
Protein degraders gain speed as Arvinas scores landmark approval

Image: PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice →

Tags
pipelineformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
BMS’ Sotyktu secures EC approval for psoriatic arthritis
PipelinePharmaceutical Technology ↗
BMS’ Sotyktu secures EC approval for psoriatic arthritis
BMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic …
May 11, 2026
FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
PipelineFiercePharma ↗
FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
After a surprise rejection in January, the FDA has agreed to reconsider a T-cell therapy based on the same sin…
May 10, 2026
Entrada's stock craters as DMD data underperform expectations, handing advantage to Novartis
PipelineFierceBiotech ↗
Entrada's stock craters as DMD data underperform expectations, handing advantage to Novartis
Entrada Therapeutics’ Duchenne muscular dystrophy data have fallen well short of expectations, crashing the bi…
May 9, 2026